Introduction

Singulair, the brand name for montelukast sodium, occupies an unusual position in the respiratory medicines market. First approved by the U.S. Food and Drug Administration (FDA) in 1998, the medicine became an established oral treatment option for asthma and allergic rhinitis by targeting leukotriene-mediated inflammation rather than the corticosteroid pathway or airway smooth-muscle receptors targeted by many competing therapies.

More than two decades after its launch, Singulair is no longer primarily a story about innovative drug development. It is a case study in how a mature branded medicine can remain clinically relevant while its commercial position changes substantially because of generic competition, evolving treatment guidelines, and regulatory scrutiny over safety.

Montelukast remains available as Singulair in some markets and as numerous generic products internationally. In the United States, current prescribing information covers chronic asthma treatment, prevention of exercise-induced bronchoconstriction, and relief of seasonal and perennial allergic-rhinitis symptoms. At the same time, FDA requires a boxed warning concerning serious neuropsychiatric events and recommends reserving montelukast for allergic rhinitis when alternative therapies are ineffective or not tolerated.

This combination of established efficacy, oral administration, broad historical use, generic availability, and safety considerations makes Singulair relevant to pharmaceutical companies, healthcare providers, payers, regulators, and manufacturers competing in respiratory medicine.

From a healthcare market perspective, montelukast illustrates an important transition: the commercial value of a mature medicine is increasingly determined not only by its original clinical differentiation, but also by prescribing guidelines, safety communication, manufacturing economics, generic competition, and the availability of alternative therapies.

What Is Singulair?

Singulair is the original brand of montelukast, a leukotriene receptor antagonist (LTRA). Montelukast blocks the cysteinyl leukotriene type 1 receptor, reducing the effects of leukotrienes that contribute to airway inflammation, bronchoconstriction, and symptoms associated with allergic airway disease.

Unlike inhaled corticosteroids (ICS), montelukast is not a corticosteroid. It is administered orally and has been developed in tablet, chewable-tablet, and oral-granule formulations. These characteristics historically helped differentiate it from inhaled respiratory medicines, particularly in pediatric treatment settings and for patients for whom an oral option was considered useful.

The FDA-approved role of montelukast includes prophylaxis and chronic treatment of asthma, prevention of exercise-induced bronchoconstriction, and relief of symptoms associated with seasonal and perennial allergic rhinitis. Current U.S. labeling includes pediatric formulations, although the specific age range varies according to the indication and dosage form.

Montelukast is not intended to treat an acute asthma attack. Its role is preventive or maintenance-oriented rather than that of a rescue medication.

The clinical position of montelukast has changed as asthma treatment strategies have become more focused on inhaled anti-inflammatory therapy. The Global Initiative for Asthma (GINA) 2025 strategy report describes leukotriene receptor antagonists as less effective than daily inhaled corticosteroids for preventing exacerbations and notes that montelukast is associated with concerns about serious behavioral and mood changes.

This does not make montelukast irrelevant. Instead, it places the medicine in a more selective position within asthma management. Oral administration, treatment of exercise-induced bronchoconstriction, and the coexistence of asthma and allergic rhinitis can still make leukotriene-pathway treatment clinically relevant in appropriate patients.

Approved use Versus Broader Research

Montelukast has also appeared in research involving conditions beyond its established indications. Such investigations should not be confused with regulatory approvals.

The strongest commercial foundation remains asthma, exercise-induced bronchoconstriction, and allergic rhinitis. Research into other inflammatory, neurological, or respiratory conditions may provide scientific insight into leukotriene biology, but investigational findings do not automatically translate into approved indications or commercially viable new markets.

For pharmaceutical market analysis, this distinction is particularly important because mature drugs frequently accumulate a large research literature long after their primary commercial exclusivity has ended.

Recent Developments and Trends

Safety communication remains central to montelukast's positioning

The most consequential regulatory development in the modern history of Singulair occurred in 2020, when the FDA strengthened warnings about serious neuropsychiatric events associated with montelukast and required a boxed warning.

The FDA cited reports involving a range of mental-health and behavioral effects, including suicidal thoughts or actions. Following its review of case reports, observational data, and other evidence, the agency concluded that the benefit-risk balance could be unfavorable for some patients with mild allergic rhinitis.

As a result, FDA advised that montelukast should generally be reserved for allergic-rhinitis patients who have an inadequate response or intolerance to alternative medicines. For asthma, the agency retained the indication but advised healthcare professionals to consider the benefits and risks of neuropsychiatric effects when prescribing the medicine.

This decision has implications beyond safety labeling. It affects prescribing behavior, physician education, patient counseling, treatment algorithms, and the commercial attractiveness of montelukast for allergic-rhinitis use.

Newer evidence presents a nuanced safety picture

Research published since the FDA warning has not produced a completely uniform interpretation of neuropsychiatric risk.

A 2023 systematic review examining neuropsychiatric events in asthma patients found no significant association between montelukast and suicide-related events across several observational studies and did not identify a consistent association with depression in several analyses. At the same time, pharmacovigilance and observational evidence suggested possible associations with anxiety and sleep disorders, particularly among adults.

A separate 2023 meta-analysis of randomized controlled trials found no significant overall increase in neuropsychiatric events compared with placebo.

More recently, a 2025 meta-analysis reported a modestly increased risk of anxiety while finding no consistent evidence for increased depression or suicidal behavior. The authors also emphasized the limitations of the available evidence.

The market implication is not that one study cancels another. Rather, the evidence base remains sufficiently complex that regulatory warnings continue to influence the medicine's risk-benefit positioning even as researchers continue to investigate the magnitude and characteristics of potential neuropsychiatric effects.

Asthma guidelines increasingly favor inhaled anti-inflammatory therapy

Current asthma treatment strategies provide another structural challenge for montelukast.

GINA's 2025 guidance places leukotriene receptor antagonists below inhaled corticosteroid-based approaches in terms of effectiveness for preventing asthma exacerbations. Montelukast may be used as an option for maintenance therapy, particularly in children, but when used alone it is less effective than low-dose ICS and, when added to ICS, less effective than ICS-LABA therapy.

This changes the competitive environment. Montelukast is not competing only against other oral medicines. It competes within treatment pathways increasingly dominated by inhaled corticosteroids, combination inhalers, long-acting bronchodilators, and, for severe asthma, targeted biologic therapies.

The result is a more segmented commercial role rather than the broad positioning the medicine enjoyed during earlier stages of its lifecycle.

Singulair remains commercially present in selected markets

Despite its mature status, Singulair has not disappeared from international pharmaceutical markets.

Current UK medicines information lists Singulair 10 mg film-coated tablets and pediatric 5 mg chewable tablets under Organon Pharma (UK) Limited. The electronic medicines compendium also lists multiple generic montelukast products from companies including Aurobindo, Dr. Reddy's Laboratories, Glenmark, Krka, and Sandoz.

The UK product database recorded updates to Singulair prescribing information in September 2026, indicating that the branded product remains part of the active regulatory and commercial environment in that market, even though certain pediatric presentations have also been marked discontinued.

This illustrates an important feature of mature pharmaceuticals: brand presence can persist in selected countries even after the market has become highly genericized.

Generic competition has reshaped the commercial landscape

Montelukast has been available in generic form for many years. FDA records, for example, document approval of generic montelukast tablets therapeutically equivalent to Singulair.

Generic competition changes the economics of the product. Instead of competing primarily through discovery-stage innovation, manufacturers compete through supply reliability, regulatory compliance, manufacturing efficiency, formulation breadth, distribution, contracting, and price.

This is particularly relevant for oral respiratory medicines because multiple manufacturers can serve pharmacies, wholesalers, health systems, and national procurement programs.

Impact on the Healthcare Industry

Singulair's industry impact extends beyond its direct clinical use.

Patients and healthcare providers

Montelukast provides an oral therapeutic option within respiratory care, including pediatric formulations and treatment for exercise-induced bronchoconstriction. Oral administration can be commercially relevant because medication-delivery preferences and practical barriers influence treatment selection.

At the same time, the boxed warning means that prescribing decisions require greater attention to neuropsychiatric safety. This adds a counseling and monitoring dimension that was less prominent during the drug's earlier commercial lifecycle.

For healthcare providers, the challenge is therefore one of patient selection. Montelukast may remain useful in specific clinical circumstances, but its position is less straightforward than simply being an alternative respiratory medicine.

Pharmaceutical manufacturers

For manufacturers, montelukast represents a mature, high-volume generic opportunity rather than a conventional innovation opportunity.

Production economics can still matter because asthma and allergic rhinitis are widespread conditions, while oral formulations can support multiple product configurations. Companies able to maintain reliable supply and competitive manufacturing costs can participate in the market without developing a new active pharmaceutical ingredient.

The downside is limited differentiation. When multiple manufacturers sell therapeutically equivalent products, price pressure can become more important than brand recognition.

Healthcare systems and payers

Generic competition can support lower-cost access compared with patented respiratory medicines, particularly where procurement systems actively encourage generic substitution.

At the same time, the cost-effectiveness question cannot be separated from clinical positioning. A low-cost medicine is not automatically the preferred treatment if another therapy provides better disease control for a particular population.

For payers, the relevant question is therefore not simply the acquisition price of montelukast. It is how the drug fits into the broader treatment pathway, including asthma control, exacerbation prevention, adherence, adverse-event monitoring, and use of alternative therapies.

Regulatory systems

Montelukast also demonstrates how post-market pharmacovigilance can reshape a mature pharmaceutical.

The 2020 FDA boxed warning did not remove the drug from the market. Instead, it changed how the medicine should be positioned and communicated, especially for allergic rhinitis.

This type of regulatory intervention can have a commercial effect without resulting in withdrawal. Manufacturers may retain the product while prescribers shift its use toward narrower patient populations.

Market and Business Implications

A mature market with selective commercial opportunities

Montelukast is best understood as a mature pharmaceutical segment with continued demand rather than a conventional high-growth branded opportunity.

The original Singulair franchise benefited historically from its oral route, broad respiratory indications, pediatric formulations, and recognition among prescribers. Today, those advantages are moderated by generic competition and the availability of other treatment classes.

For generic manufacturers, the opportunity is different. The commercial model is based on maintaining market access and operational efficiency rather than building a premium brand.

Competition is increasingly formulation- and geography-driven

The existence of multiple montelukast manufacturers means competition can differ considerably between countries.

In the UK, for example, current medicines information lists generic suppliers alongside Singulair. Similar competitive structures exist across other markets where generic pharmaceutical manufacturing is well established.

This creates opportunities for companies with established regulatory infrastructure in multiple regions. Pediatric chewable tablets and oral granules may also create differentiated niches within an otherwise commoditized active ingredient, provided manufacturers can satisfy local regulatory and supply requirements.

Respiratory portfolios are shifting toward combination and targeted therapies.

The broader asthma market has moved toward inhaled corticosteroid combinations and targeted biologic therapies for severe disease. This places a ceiling on how far montelukast can expand its role within modern asthma treatment.

For pharmaceutical companies, the strategic question is therefore whether montelukast is best treated as an individual product or as part of a broader respiratory portfolio.

Companies with strong generic respiratory portfolios can use established distribution channels and manufacturing capabilities to support montelukast alongside other asthma and allergy medicines. In contrast, innovative pharmaceutical companies are more likely to prioritize novel inhaled therapies, biologics, and precision-treatment approaches where greater differentiation is possible.

India and other generic manufacturing hubs

India remains particularly relevant to the global generic pharmaceutical ecosystem. Companies such as Cipla, Dr. Reddy's Laboratories, Glenmark, Lupin, Sun Pharmaceutical Industries, and Aurobindo have broad respiratory or generic portfolios and participate in international pharmaceutical markets.

Montelukast illustrates why established generic products continue to matter for manufacturers in these markets. Even when the molecule itself is no longer innovative, manufacturing scale, regulatory approvals, product breadth, and access to international distribution networks can sustain commercial opportunities.

The main challenge is margin pressure. Mature generic products can become increasingly price-sensitive as more suppliers enter or remain in the market.

Key Companies and Industry Participants

Merck & Co.

Merck developed Singulair and received FDA approval for the product in 1998 after research into leukotriene blockers. The original innovation story remains important because montelukast helped establish leukotriene receptor antagonism as a practical therapeutic approach in respiratory medicine.

Merck's historical role is therefore primarily that of the originator and developer of Singulair.

Organon

Organon is relevant to the current branded Singulair landscape in markets where the product is commercialized under Organon's regional operations. Current UK medicines information identifies Organon Pharma (UK) Limited as the company associated with Singulair products.

Its role demonstrates how the ownership and commercialization of established pharmaceutical brands can change over time as companies restructure portfolios and separate businesses.

Generic manufacturers

Aurobindo, Dr. Reddy's Laboratories, Glenmark, Sandoz, Krka, Teva, Viatris, Sun Pharma, Cipla, and other manufacturers participate in the broader montelukast ecosystem across different markets and formulations.

Their importance is not simply the number of companies involved. The presence of numerous suppliers changes pricing dynamics, increases substitution opportunities, and makes manufacturing reliability a major competitive factor.

FDA, EMA and national regulators

Regulators remain central stakeholders because montelukast's market position depends on product labeling, pharmacovigilance, manufacturing quality, and national prescribing frameworks.

The FDA's boxed-warning decision remains particularly influential in the United States, while European national and regional regulatory systems continue to maintain product information and market authorizations for montelukast products.

GINA and clinical organizations

GINA does not manufacture medicines, but its treatment recommendations can have substantial indirect market effects. By placing LTRAs below inhaled corticosteroid-based approaches for many asthma treatment scenarios, the guideline helps shape clinical demand and competitive positioning.

Challenges and Limitations

The most important limitation surrounding Singulair is its changing benefit-risk position.

The neuropsychiatric safety issue remains commercially significant even though published studies have produced mixed findings. A boxed warning can affect prescribing behavior for years because physicians, patients, and healthcare organizations incorporate regulatory risk communication into treatment decisions.

A second challenge is therapeutic competition. In asthma, inhaled corticosteroids and ICS-containing combinations occupy central positions in guideline-based management. Severe asthma has also become increasingly segmented through biologic therapies targeting specific inflammatory pathways.

A third limitation is generic commoditization. Multiple suppliers reduce the ability to differentiate a mature active ingredient through conventional brand positioning. Manufacturers must compete through quality, availability, regulatory execution, contracting, and distribution.

Supply continuity can also matter. Mature generic medicines are often exposed to price competition that can reduce the economic attractiveness of production for individual suppliers. If manufacturing becomes concentrated among fewer viable suppliers, procurement organizations can become more sensitive to shortages or disruptions.

Another challenge is the difference between regulatory labeling and clinical practice. Montelukast remains approved for several indications, but guidelines and safety communications can narrow how physicians use those indications in practice. This creates a gap between formal market authorization and effective commercial demand.

Finally, international markets are not uniform. Availability of Singulair, generic substitution rules, pricing structures, reimbursement, age-specific labeling, and treatment guidelines vary by country. Pharmaceutical companies therefore need country-level analysis rather than assuming that the commercial position of montelukast in the United States reflects its position globally.

Future Outlook

The future of Singulair is likely to be shaped less by new molecular innovation and more by how the healthcare system positions a mature therapy.

For asthma, montelukast is likely to remain a selective oral option rather than displace inhaled corticosteroid-based treatment strategies. GINA's current recommendations provide a clear indication of the competitive environment in which leukotriene receptor antagonists operate.

For allergic rhinitis, the FDA's restriction-oriented safety communication is likely to continue limiting montelukast's attractiveness relative to other allergy therapies, particularly for patients who can obtain adequate symptom control from alternatives.

Generic manufacturers are likely to remain important because montelukast has an established regulatory pathway and a large installed clinical base. The competitive emphasis should remain on manufacturing economics, regulatory compliance, supply reliability, formulation availability, and geographic reach.

Pediatric formulations may remain commercially relevant because montelukast has historically been available in age-specific dosage forms. Nevertheless, pediatric demand must be considered alongside evolving safety communication and treatment guidelines rather than assumed to be a standalone growth opportunity.

Another area to watch is post-market evidence. Continued pharmacoepidemiology and real-world safety research may refine understanding of neuropsychiatric risks and identify patient characteristics associated with greater susceptibility. Such evidence could influence future prescribing recommendations, regulatory communications, and market segmentation.

For healthcare market researchers and pharmaceutical strategists, Singulair therefore offers a useful example of lifecycle management. The commercial question is no longer whether montelukast can establish a market; it has already done so. The more relevant questions involve how the remaining market is divided among branded and generic suppliers, which patient populations continue to receive the medicine, how safety considerations influence demand, and where manufacturing economics remain attractive.

Conclusion

Singulair represents one of the more established oral therapies in modern respiratory medicine. Developed by Merck and approved by the FDA in 1998, montelukast introduced a leukotriene-receptor approach that became widely used for asthma, exercise-induced bronchoconstriction, and allergic rhinitis.

Its current position is more selective. Generic competition has changed the commercial structure of the market, while modern asthma guidelines favor inhaled corticosteroid-based strategies for many patients. The FDA's 2020 boxed warning concerning serious neuropsychiatric events has also materially influenced the medicine's risk-benefit profile, particularly in allergic rhinitis.

Yet montelukast remains commercially and clinically relevant. Active branded products continue to exist in some markets, generic manufacturers supply multiple formulations, and the medicine retains approved roles within respiratory care.

For the pharmaceutical industry, Singulair is therefore less a story of a declining product than an example of pharmaceutical lifecycle maturity. Its future market position will depend on selective clinical use, generic supply economics, regulatory oversight, safety evidence, and the competitive strength of newer respiratory therapies. The product's long history also demonstrates how regulatory decisions and changing treatment standards can reshape the commercial trajectory of a medicine long after its original launch.

Source References

• U.S. Food and Drug Administration (FDA) - FDA Requires Boxed Warning About Serious Mental Health Side Effects for Asthma and Allergy Drug Montelukast (Singulair); Advises Restricting Use for Allergic Rhinitis.
• U.S. Food and Drug Administration - Singulair (montelukast) and All Montelukast Generics: Strengthened Boxed Warning.
• Merck & Co. - SINGULAIR Prescribing Information.
• Merck & Co. - Company History: 1998 SINGULAIR Approved by FDA.
• DailyMed - Montelukast Sodium Tablets, Prescribing Information.
• Global Initiative for Asthma (GINA) - GINA 2025 Strategy Report.
• Global Initiative for Asthma (GINA) - GINA 2025 Summary Guide.
• European Medicines Agency (EMA) - Singulair Referral.
• European Medicines Agency - Montelukast: List of Nationally Authorised Medicinal Products.
• Electronic Medicines Compendium (emc) - Medicines Containing the Active Ingredient Montelukast Sodium.
• Lo CW-H, et al. - Neuropsychiatric Events Associated With Montelukast in Patients With Asthma: A Systematic Review. European Respiratory Review, 2023.
• Meta-analysis of the Relationship Between Montelukast Use and Neuropsychiatric Events in Patients With Allergic Airway Disease, 2023.
• Sobczak M, Pawliczak R. - Montelukast: Risk of Mental Disorders vs. Efficacy-A Meta-analysis. Frontiers in Pharmacology, 2025.
• World Health Organization (WHO) - The Selection and Use of Essential Medicines, 2025: WHO Model List of Essential Medicines, 24th List.
• U.S. FDA - Abbreviated New Drug Application approval documentation for generic montelukast sodium tablets.